Kenvue Inc. Common Stock (KVUE)

Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66

Kimberly Clark is a worthy foundational holding in a passive-income portfolio.

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing

NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across the board. On April 14, 2026, the healthcare titan announced it was raising its full-year 2026 revenue and earnings guidance, signaling that

As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue, in 2023, the New Brunswick-based giant has shed its "band-aid and baby powder" image to emerge as a high-octane, pure-play healthcare powerhouse. [...]

The choice is based on more than just the dividend payout.

These defensive consumer stocks are flashing buy signals while the market chases AI hype.

As the sun sets on the era of easy profits from elevated interest rates, the titans of Wall Street are preparing to unveil a new chapter in their growth stories. For the first time in three years, the narrative surrounding the upcoming Q1 2026 earnings for Goldman Sachs (NYSE: GS)

This Dividend King drug maker's dividend yield is roughly twice that of the S&P 500 index.

The global financial landscape underwent a seismic shift in the first quarter of 2026, as a "perfect storm" of stabilizing interest rates and technological urgency triggered a historic wave of mergers and acquisitions. Total deal volume for the quarter reached a staggering $1.25 trillion, marking a 26% increase over

Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry.

Buying stocks at incredibly low valuations often comes with risk, but it may also result in massive returns.

The first quarter of 2026 has officially marked the end of the deal-making drought, ushering in a lucrative "advisory windfall" for Wall Street’s elite investment banks. Driven by a surge in multi-billion dollar tech and healthcare integrations, total global M&A volume reached a staggering $1.38 trillion in

Shares of Johnson & Johnson have fallen by less than 2% over the past month, while the S&P 500 has fallen by more than 7%.

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed its legacy consumer health business and weathered the initial storm of its largest patent cliff in a decade, J&J has rebranded itself as a [...]

As the first quarter of 2026 draws to a close, the global mergers and acquisitions (M&A) market has delivered a paradox that is reshaping the financial landscape. Preliminary data reveals that total deal values surged to a record-breaking $813.3 billion in Q1, a staggering leap that signals a

In a move that signals a bold return to aggressive brand acquisition, Prestige Consumer Healthcare Inc. (NYSE: PBH) announced on March 20, 2026, that it has entered into a definitive agreement to acquire the iconic Breathe Right nasal strip brand. The $1.045 billion cash transaction with Foundation Consumer Healthcare

This stock is one to own during any market environment.

Capitalize on near-term bearishness with these two high-quality dividend stocks.

In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health titan Kenvue (NYSE:KVUE). Announced in late 2025 and overwhelmingly approved by shareholders in January 2026, the deal

While recent performance trails the industry, Kenvue continues to retain measured analyst confidence and long-term relevance.

These Dividend Kings offer price appreciation potential alongside dividend growth.

Seven of Wall Street's most influential businesses are doling out between $11.9 billion and $27.1 billion to their investors each year.